Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)

NCT03152058 is registered in ClinicalTrials.gov with David Ware Branch as lead sponsor.

NCT NCT03152058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03152058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)
Lead sponsor
David Ware Branch
Phase
Phase 2
Overall status
Recruiting
Start date
May 17, 2017
Completion date
December 31, 2027
Enrollment
55 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome in pregnancy, high risk pregnancy, lupus anticoagulant disorder, pregnancy complications